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Do insulin-sensitizing drugs
increase ovulation rates 
for women with PCOS?
■ EVIDENCE-BASED ANSWER
Short-term use of metformin (Glucophage)
improves ovulation rates for women with poly-
cystic ovary syndrome (PCOS) (strength of rec-
ommendation [SOR]: A, based on systematic
reviews of randomized controlled trials [RCT]).
Metformin also decreases menstrual irregulari-
ties (SOR: B, extrapolated from a systematic
review). When added to clomiphene, metformin
increases ovulation and pregnancy rates when
compared with clomiphene alone (SOR: A, 
systematic review). 
Thiazolidinediones (TZDs) improve ovulation
rates as well (SOR: B, based on low-quality
RCTs). Research of longer duration including the
key outcomes of pregnancy and birth rates, is
needed to clarify the appropriate use of insulin-
sensitizing drugs for PCOS.
■ EVIDENCE-BASED SUMMARY
A common female endocrinopathy, PCOS affects
5% to 10% of women. Characterized by anovula-
tion and hyperandrogenism, it often manifests as
infertility and irregular menstruation. Metformin
and thiazolidinediones are likely effective treat-
ments for these expressions of insulin resistance,
but study limitations restrict our ability to clearly
define their role. 
The most influential systematic review was a
meta-analysis that reviewed 13 RCTs including
543 women to determine the effects of metformin
on ovarian function in PCOS.1,2 By selecting RCTs,
performing precise statistical analysis according
to the Cochrane protocols, and clearly stating lim-
itations, this review gives good evidence that
metformin modestly increases the odds of ovula-
tion for women with PCOS (odds ratio [OR]=3.88;
95% confidence interval [CI], 2.25–6.69 for met-
formin vs placebo) and that metformin with
clomiphene (Clomid) effectively increases ovula-
tion (OR=4.41; 95% CI, 2.37–8.22) and pregnan-
cy rates (OR=4.40; 95% CI, 1.96–9.85) when
compared with clomiphene use alone. When met-
formin is used as a sole agent, ovulation is
achieved in 46% of recipients compared with 24%
in the placebo arm (number needed to treat
[NNT]=4.4). When metformin and clomiphene are
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clinical relevance.4 Metformin improves ovulation
and menstrual cyclicity but these improvements
were variable and modest. On average, 1 addi-
tional ovulation is attained in every 5-month inter-
val with metformin treatment; specifically, the
baseline of 1 ovulation per 5-month interval
increased to 2 ovulations per 5-month interval.
Spontaneous ovulation and normal menstruation
are achieved rapidly (within 3 months of the start
of therapy). These data corroborate the benefits 
of metformin but place its clinical significance 
in perspective. For PCOS patients seeking cycle
regulation but not pregnancy, oral contraceptives
may remain better therapy because metformin
does not normalize menses.
Less information exists on the role of TZDs
and ovarian function in PCOS. Studies of the
most researched drug in the class, troglitazone
(Rezulin), report improvements in ovulation rates
and metabolic markers of PCOS.5,6 Troglitazone
has been taken off of the market due to hepato-
toxicity, but results from a RCT of 40 patients
with PCOS reported that the use of pioglitazone
(Actos) for 3 months increased normal regular
cycles and ovulations over placebo (41.2% vs
5.6%; P<.02).7 No liver effects were noted, but
caution must be taken since these drugs are
pregnancy class C. Two small RCTs studied the
use of rosiglitazone (Avandia) in combination
with clomiphene and reported improvements in
menstrual regularity8 (92% with combination
therapy achieved improved menstrual cycles vs
68% with rosiglitazone alone; OR=0.185) and
both spontaneous and clomiphene-induced ovula-
tion rates (52% of clomiphene-resistant women
ovulated after rosiglitazone therapy and 77% 
vs 33% ovulated with combination therapy vs
rosiglitazone alone, P=.04).9 Further research 
is needed to determine the clinical effects of the
thiazolidinediones.
used in combination, 76% of recipients ovulate
compared with 42% receiving clomiphene alone
(NNT=3.0). 
Several problems with recommending met-
formin as first-line therapy exist: (1) equal or
better ovulation rates have been described by
using lifestyle interventions to achieve weight
loss, (2) there are no long-term studies of the
effects of metformin in PCOS patients, and (3)
we cannot assess the clinically important out-
come of pregnancy rates because the trials did
not control for other infertility factors and did not
define live births as a primary outcome. In addi-
tion, there are no head-to-head trials of met-
formin vs clomiphene, the standard first-line
therapy for ovulation induction. Only 1 study
addressed menstrual patterns specifically; they
were improved with metformin (OR=12.88; 95%
CI, 1.85–89.61). 
An additional meta-analysis reports similar
results.3 Eight RCTs addressing the use of met-
formin or clomiphene for treatment of PCOS were
reviewed for ovulation and pregnancy rates.
Metformin is 50% better than placebo for ovula-
tion induction among infertile PCOS patients 
(relative risk [RR]=1.50; 95% CI, 1.31–1.99), but
this benefit is not necessarily improved 
with longer duration (>3 months) of therapy
(RR=1.37; 95% CI, 1.05–1.79). Also, metformin
is beneficial in regulating cycles for fertile PCOS
patients with irregular menses (RR=1.45; 95%
CI, 1.11–1.90). 
The conclusions regarding pregnancy rates and
combined therapy with metformin and clomiphene
are limited due to small samples, short follow-up
time (2–6 months), and study design. An ongoing
randomized trial (Pregnancy in Polycystic Ovarian
Syndrome: PPOS study) of 768 infertile PCOS
patients is investigating effects of metformin vs
clomiphene on ovulation induction and achieve-
ment of singleton pregnancies. These outcomes
should clarify remaining uncertainties regarding
appropriate use of metformin.
Finally, a review of 7 RCTs describes the evi-
dence accumulated by well-designed trials and its
For PCOS patients seeking cycle
regulation, oral contraceptives 
may remain the better therapy
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■ RECOMMENDATIONS FROM
OTHERS
The American College of Obstetricians and
Gynecologists guideline on diagnosis and man-
agement of PCOS reports that interventions that
improve insulin sensitivity, including weight loss,
use of metformin, and use of TZDs are useful for
improving ovulatory frequency for women with
PCOS.10 The recommendation is based on good
and consistent scientific evidence (SOR: A). They
also note that insulin-sensitizing agents may
improve many risk factors for diabetes and car-
diovascular disease, but this recommendation is
based on limited evidence (SOR: B). Finally, they
recommend, based on expert opinion (SOR: C),
that caution be used with these agents because
their effects on early pregnancy are unknown,
even though metformin appears to be safe. 
The American Association of Clinical
Endocrinologists recommends using metformin
850 mg twice daily to treat the hyperandrogenic
state of PCOS.11 The use of TZDs is less clear due
to limited evidence and risks of teratogenicity. 
Camille Andy, MD, Moses Cone Family Medicine
Residency Program, Greensboro, NC; Donna Flake,
MSLS, MSAS, Coastal AHEC Library, Wilmington, NC
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■ CLINICAL COMMENTARY
For those trying to conceive, the tried-and-
true medication is clomiphene
I tend to think of women with PCOS as falling
into 2 camps, those actively trying to conceive
and those who are not. Those who are not can
often get benefits for their menstrual cycles
and hyperandrogenism with birth control pills.
For those trying to conceive, the tried-and-true
first-line medication is clomiphene. 
Metformin has been figuring prominently in
the literature as adjunct or second-line therapy
for infertility for women with PCOS. It is also an
accepted treatment for hirsutism. So, for women
with PCOS, metformin is a treatment that
bridges the 2 camps. I look forward to seeing
head-to-head trials of metformin, clomiphene,
and both therapies for induction of ovulation. 
Linda French, MD, Department of Family Practice,
